Clinical Trials on Severe/Very Severe COVID-19 Illness

Total 573 results

Novartis Pharmaceuticals
Novartis is the Marketing Authorization Holder for Jakavi outside the US.

No longer available

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

Severe/Very Severe COVID-19 Illness
LG Life Sciences

Unknown

Clinical Study to Evaluate the Efficacy and Safety of YVOIRE® Contour Compared With Restylane SubQ™ Injected Into the Anteromedial Malar Region

Normal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region

Korea, Republic of
LG Life Sciences

Completed

Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study

Normal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region Who Have Completed the LG-HACL014 Study

Korea, Republic of
National Institute of Allergy and Infectious Diseases...
Mexican Emerging Infectious Diseases Clinical Research Network

Completed

Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness (NTZ-SARI)

Severe Acute Respiratory Illness

Mexico
Hospices Civils de Lyon

Unknown

Senior-COVID-Rea Multicentric Survey (SeniorCOVIDRea)

COVID-19 Disease, Severe Form

France
Shalvata Mental Health Center

Active, not recruiting

Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness

Severe Mental Illness

Israel
King's College London
South London and Maudsley NHS Foundation Trust

Completed

Mental Health Intervention for Transdiagnostic Groups in the Community

Severe Mental Illness

United Kingdom
Education University of Hong Kong
Baptist Oi Kwan Social Service

Completed

Effectiveness of Internet-based Self-help Money Management Program Among Adult With Severe Mental Illness

Severe Mental Illness

Hong Kong
New York University
University of Pennsylvania; Yale University

Completed

Person-Centered Care Planning and Service Engagement (PCCP)

Severe Mental Illness

United States
University of Oklahoma

Completed

Physical Activity for People With Behavioral Diagnoses

Severe Mental Illness

United States
Centre Hospitalier Universitaire Dijon

Completed

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen (COVIDOLIP)

COVID-19 Severe Pneumonia | Severe Pneumonia Due to Other Pathogene

France
Oulu University Hospital
University of Oulu

Recruiting

Effectiveness of Mentalization-based Therapy (MBT)

Severe Mental Illness

Finland
University of Groningen
Lentis Psychiatric Institute; GGZ Friesland; Stichting Cosis

Recruiting

Cognitive Remediation and Transcranial Direct Current Stimulation in Severe Mental Illness (SMI) (HEADDSET+)

Severe Mental Illness

Netherlands
Shalvata Mental Health Center

Recruiting

The Effects of Oxytocin Administration to Patients and Therapists on Physiological Synchronization

Severe Mental Illness

Israel
Indiana University

Completed

Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development (IT IS VALID)

Severe Mental Illness
GGZ Centraal
ZonMw: The Netherlands Organisation for Health Research and Development

Not yet recruiting

Evaluation of Combined Support for the Ambulatory Lifestyle Intervention (GOAL!)

Lifestyle | Severe Mental Illness

Netherlands
Kythera Biopharmaceuticals

Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (REFINE-1)

Moderate or Severe Submental Fullness

United States, Canada
Universidad Pablo de Olavide

Unknown

Exercise in Severe Mental Illness. The PsychiActive Project 2.0

Exercise Therapy | Severe Mental Illness

Spain
Sichuan Huiyu Pharmaceutical Co., Ltd
Peking Union Medical College Hospital; First Affiliated Hospital Xi'an Jiaotong...

Recruiting

A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

Moderate or Severe Submental Fullness

China
AMIpharm Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat (AYP-101)

Moderate or Severe Submental Fullness

Korea, Republic of
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Belgium, France, Germany, Italy, Spain, United Kingdom
AMIpharm Co., Ltd.

Completed

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Moderate or Severe Submental Fullness

Korea, Republic of
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada
Tilburg University
Stichting tot steun VCVGZ; Trimbos-institute (also primary organization conducting... and other collaborators

Active, not recruiting

Investigating the Meaning and (Cost-)Effectiveness of Dutch Recovery Colleges

Severe Mental Illness | Mental Vulnerabilities

Netherlands
IRCCS Centro San Giovanni di Dio Fatebenefratelli

Not yet recruiting

Real-time Experiences, Physical Activity and Biological Outcomes in Personal Recovery Residents (EMPOWER-RES) (EMPOWER-RES)

Severe Mental Disorder | Severe Mental Illness
Kansas State University
Augusta University; Dartmouth College; University of Cincinnati

Enrolling by invitation

Physical Activity to Reduce Cardiometabolic Risk in Adults With Serious Mental Illness (PARCS) Study (PARCS)

Mental Disorders, Severe | Mental Illness Persistent

United States
Rambam Health Care Campus

Unknown

From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management

Patients Diagnosed With Severe Mental Illness

Israel
ANRS, Emerging Infectious Diseases
University of Bordeaux; PACCI Program

Completed

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial (INTENSE-COV)

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | COVID-19 Drug Treatment

Côte D'Ivoire
University of Giessen

Completed

GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)

COVID-19 Pneumonia | Severe Acute Respiratory Syndrome (SARS) Pneumonia

Germany
Assistance Publique - Hôpitaux de Paris

Unknown

MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients (MICROVID)

Covid-19 | Critical Illness | SARS-CoV Infection | Hemodynamics

France
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR AGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
60P Australia Pty Ltd

Not yet recruiting

A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

Infectious Disease | SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2 | COVID 19 Disease | Mild to Moderate COVID 19 Disease
Hopital of Melun

Completed

Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients (pRNA-COVID-ICU)

COVID-19 Pneumonia | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2

France
Xijing Hospital
Massachusetts General Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Withdrawn

Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. (NOSARSCOVID)

SARS (Severe Acute Respiratory Syndrome) | Coronavirus Covid-19 Infection Variant Omicron
Ministry of Health, Kuwait

Unknown

COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients

Pneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia

Kuwait
Lund University

Active, not recruiting

Development and Evaluation of an Intervention (AiMH) for People With Severe Mental Illness Living in Supported Housing

Severe Mental Disorder
Inovio Pharmaceuticals
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 Disease

United States, Mexico, Colombia
National Institute of Allergy and Infectious Diseases...
PPD; University of Washington; Vanderbilt University Medical Center; Implicit Bioscience

Terminated

COVID-19 and Anti-CD14 Treatment Trial (CaTT)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19)

United States
Emory University
National Cancer Institute (NCI)

Terminated

Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19)

Pneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) Pneumonia

United States
Asan Medical Center

Suspended

Fluvoxamine for Adults With Mild to Moderate COVID-19

Coronavirus Infection | Severe Acute Respiratory Syndrome Coronavirus 2 | Mild to Moderate COVID-19

Korea, Republic of
University of Utah
Novartis

Completed

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

Severe Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic Anemia

United States
National Institutes of Health Clinical Center (CC)

Completed

The National Institutes of Health Measure of Healing Experience of All Life Stressors (NIH-HEALS)

Severe Chronic Illness

United States
Shahid Beheshti University of Medical Sciences

Unknown

Low Dose Radiotherapy in COVID-19 Pneumonia

COVID | SARS (Severe Acute Respiratory Syndrome)

Iran, Islamic Republic of
Karadeniz Technical University

Completed

Vasopressin Use in Septic Shock From Türkiye ((VASCO-TURK))

Critical Illness | Septic Shock | Intensive Care Medicine | Vasodilatory Shock | Critical Illness Sepsis, Severe | Vasopressor Therapy

Turkey

Clinical Trials on Severe/Very Severe COVID-19 Illness

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations